DIRS.INFO The most relevant business & tech news

☆ Here are Tuesday's biggest analyst calls: Apple, Costco, Nvidia, Palantir, Broadcom, Tesla, Amazon, Meta & more
▼ + stars: | 2024-09-10 | by ( Michael Bloom | ) www.cnbc.com time to read: +5 min

"We launch coverage of GE Aerospace with an Outperform rating, target price $201." (ELF) with a Buy rating and a 12-month price target of $175 per share." "We initiate with a Buy rating on Harmony , a commercial stage biotech focused on CNS [central nervous system] disorders." "We are initiating coverage of ProKidney Corp. (PROK) with a BUY rating and $6 price target." We are initiating coverage with a BUY rating and $600 price target."

Persons: Morgan Stanley, Apple, Tesla, it's, Bernstein, Riley, Wolfe, Stryker, BUD, JMP, Redburn, BTIG, Palantir, Goldman Sachs, Nutrien, Goldman, Cantor Fitzgerald, Cantor, Melius, Johnson, Guggenheim, it's bullish, D.A, Davidson, Meta Organizations: Apple, Apple Intelligence, Intelligence, Deutsche Bank, Deutsche, GE Aerospace, GE, Inc, Anheuser, Busch InBev, Oracle, Costco, Equity, Haemonetics, Plasma Solutions, Blood Center, Hospital Care Solutions, " Bank of America, Bank of America, UBS, Amazon, Harmony Biosciences, NTR, Nvidia, Broadcom, Johnson, Johnson Controls, ProKidney Corp

Investors upped their short bets on a handful of clean energy and biotechnology stocks during the first half of July, according to FactSet data. Allogene Therapeutics held the greatest short interest of the group, at about 54% of float, with Novavax and ProKidney Corp. also appearing on the list. Short interest declined slightly in ProKidney shares. Short interest in shares declined 8.6% during the first half of July, although about 35% of its shares are sold short. saw short interest leap 10% since the end of June.

Persons: BioXcel Organizations: BioXcel Therapeutics, Allogene Therapeutics, ProKidney Corp, Research, CNBC Pro, New York Stock Exchange, Nasdaq

Search resuls for: "ProKidney Corp"

2 mentions found